291 related articles for article (PubMed ID: 29393702)
1. Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA.
Psimadas D; Valotassiou V; Alexiou S; Tsougos I; Georgoulias P
Cancer Invest; 2018 Feb; 36(2):118-128. PubMed ID: 29393702
[TBL] [Abstract][Full Text] [Related]
2. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies and prostate-specific membrane antigen.
Chang SS
Curr Opin Investig Drugs; 2004 Jun; 5(6):611-5. PubMed ID: 15242249
[TBL] [Abstract][Full Text] [Related]
8. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
[TBL] [Abstract][Full Text] [Related]
12. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
Mottaghy FM; Heinzel A; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1397-9. PubMed ID: 27118189
[No Abstract] [Full Text] [Related]
14. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
15. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
17. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
[TBL] [Abstract][Full Text] [Related]
18. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.
Wester HJ; Schottelius M
Semin Nucl Med; 2019 Jul; 49(4):302-312. PubMed ID: 31227053
[TBL] [Abstract][Full Text] [Related]
19. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer.
Dorff TB; Fanti S; Farolfi A; Reiter RE; Sadun TY; Sartor O
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():321-330. PubMed ID: 31099673
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.
Viola-Villegas NT; Sevak KK; Carlin SD; Doran MG; Evans HW; Bartlett DW; Wu AM; Lewis JS
Mol Pharm; 2014 Nov; 11(11):3965-73. PubMed ID: 24779727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
